[Multidrug resistance of malignant tumors].
The development of resistance to chemotherapy is a major problem in the treatment of malignant tumors. Clinically, this is characterized by short periods of remission and failure to respond to subsequent therapy. Multidrug-resistance or pleiotropic resistance describes the simultaneous expression of cellular resistance to a vide range of structurally unrelated drugs (e.g. alkaloids, anthracyclines, antibiotics, etc.). The most frequently reported alteration of multidrug-resistant cells is the overexpression of a 170 kD glycoprotein (P--170 or P-glycoprotein) encoding by the MDR gene family. A great deal of evidence has suggested that the P-glycoprotein is, in fact, an energy-dependent drug efflux pump. Pharmacological overcome of MDR may indicate to circumvent clinically observed drug resistance.
Bak
M
M
Citodiagnosztikai Osztály, Országos Onkológiai Intézet, Budapest.
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000911:Antibodies, Monoclonal; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D004351:Drug Resistance; D006801:Humans; D007150:Immunohistochemistry; D008562:Membrane Glycoproteins / Q000378:metabolism; D009363:Neoplasm Proteins / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D010641:Phenotype
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000911:Antibodies, Monoclonal; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins
A rosszindulatú daganatok multidrug rezisztenciája.